IGM Biosciences, Inc. (IGMS)

IGM Biosciences, Inc. (IGMS) — VMCI valuation read

IGMS screens at VMCI 47/100, a 3-point gap below the Healthcare sector median (50). For a mid-cap IGM Biosciences, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

IGMS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: IGMS trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.3x leaves covenant headroom, which sets the rate-cycle exposure for IGM Biosciences, Inc..

IGMS rose 2.8% over the trailing 7 days, with a -17.4% read on a 30-day basis.